Support Melatonin Receptor Research with Standardized MT1 Peptide (5mg Specification)

If needed, please add me on WhatsApp at +852 5487 8366 and I’ll send you our product price list.

Smart Sunless Tanning with Built‑In Skin Protection

MT1 (afamelanotide) is a synthetic analogue of α‑melanocyte‑stimulating hormone (α‑MSH) that acts as a potent melanocortin 1 receptor (MC1R) agonist. Its primary clinical indication is for photoprotection in patients with erythropoietic protoporphyria (EPP), a rare genetic disorder that causes severe photosensitivity. By stimulating melanin production, MT1 increases skin pigmentation, thereby reducing painful sun reactions and improving quality of life. In addition to this orphan disease indication, MT1 has been studied for the prevention of actinic keratosis and non‑melanoma skin cancers in immunosuppressed patients.

Importantly, MT1 also exerts anti‑inflammatory effects on the skin, reducing UV‑induced immune suppression. Ongoing research is investigating its role in vitiligo repigmentation and in modulating appetite, given that MC1R is involved in energy homeostasis. For patients with EPP, MT1 has been a game‑changer, allowing them to spend time outdoors without debilitating pain. Its mechanism is elegantly simple—mimicking the body’s own tanning hormone—yet its implications are profound for dermatology and photomedicine. However, the cost and availability remain barriers, and long‑term safety data are still being collected. Users should avoid excessive sun exposure during treatment to prevent potential DNA damage, as melanin alone does not guarantee full protection. Overall, MT1 offers a medically sound, targeted approach to pigmentation and photoprotection, distinct from the more controversial MT2.